Croda International/£CRDA
1D1W1MYTD1Y5YMAX
Capital at risk
About Croda International
Founded in 1925, Croda International Plc is a UK-based speciality chemicals company recognized globally for its innovative approach to delivering specialized chemical solutions across a broad range of industries including consumer care and life sciences. Operating within the basic materials sector, Croda develops, manufactures, and markets a wide array of specialty chemicals used in everything from cosmetics and pharmaceuticals to lubricants and plastics. Over the decades, Croda has committed to sustainability and innovation, driving its growth and solidifying its position as in the industry.
- Ticker
- £CRDA
- Sector
- Materials
- Primary listing
- LSE
- Employees
- 5,954
- Headquarters
- Goole, United Kingdom
- Website
- www.croda.com
CRDA Metrics
BasicAdvanced
£4.7B
58.45
£0.57
0.92
£1.11
3.34%
Price and volume
Market cap
£4.7B
Beta
0.92
52-week high
£35.20
52-week low
£24.78
Average daily volume
547K
Dividend rate
£1.11
Financial strength
Current ratio
2.569
Quick ratio
1.563
Long term debt to equity
32.625
Total debt to equity
35.787
Dividend payout ratio (TTM)
194.72%
Interest coverage (TTM)
4.49%
Profitability
EBITDA (TTM)
244.8
Gross margin (TTM)
43.69%
Net profit margin (TTM)
4.61%
Operating margin (TTM)
7.28%
Effective tax rate (TTM)
27.90%
Revenue per employee (TTM)
£290,000
Management effectiveness
Return on assets (TTM)
2.24%
Return on equity (TTM)
3.68%
Valuation
Price to earnings (TTM)
58.447
Price to revenue (TTM)
2.688
Price to book
2.13
Price to tangible book (TTM)
5.03
Price to free cash flow (TTM)
25.405
Free cash flow yield (TTM)
3.94%
Free cash flow per share (TTM)
1.31
Dividend yield (TTM)
3.34%
Growth
Revenue change (TTM)
3.36%
Earnings per share change (TTM)
-43.14%
3-year revenue growth (CAGR)
-2.20%
10-year revenue growth (CAGR)
4.35%
3-year earnings per share growth (CAGR)
-25.70%
10-year earnings per share growth (CAGR)
-8.93%
3-year dividend per share growth (CAGR)
0.92%
10-year dividend per share growth (CAGR)
4.16%
What the Analysts think about CRDA
Analyst ratings (Buy, Hold, Sell) for Croda International stock.
Analyst projections of the future price of Croda International stock.
Bulls say / Bears say
Croda delivered 4.6% organic sales growth in H1 2026 driven by 8% growth in Consumer Care, while adjusted operating profit rose 6.7% to £155.8m with margin expansion to 17.7%, reflecting successful innovation-led growth and transformation benefits (Reuters via TradingView)
New & Protected Products grew 6.9% organically in H1, outpacing total sales growth and underscoring Croda’s strong pipeline of innovative, high-margin offerings (Reuters via TradingView)
Free cash flow post exceptionals rose 36.8% to £38.3m in H1, supported by disciplined capital expenditure, strengthening Croda’s cash generation for reinvestment and shareholder returns (Reuters via TradingView)
Foreign currency translation adversely impacted H1 adjusted operating profit by £1m, with a potential further £4m drag on FY26 results if current FX rates persist, posing a notable earnings headwind (Reuters via TradingView)
The Industrial Specialties segment saw a 1.9% decline in organic sales and a 19.8% drop in adjusted profit in H1, highlighting ongoing demand weakness and margin pressure in that unit (Reuters via TradingView)
Pharma Solutions revenues fell 17% in H1 due to project phasing, underscoring lumpy project-based income and potential volatility in future quarters (Reuters via TradingView)
Data summarised monthly by Lightyear AI. Last updated on 24 Aug 2026.
CRDA Financial Performance
Revenues and expenses
CRDA Earnings Performance
Company profitability
Upcoming events
Funds containing CRDA
AllEURGBPUSD
Fund name | Fund size | £CRDA weighting |
|---|---|---|
iShares STOXX Europe 600 Chemicals€EXV7 | €104M | 2.37% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.35% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.35% |
iShares STOXX Europe Mid 200€EXSD | €610M | 0.31% |
Vanguard FTSE 100£VUKE | £4.8B | 0.17% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.